Interpreting genomic test results for cancer care remains a significant challenge, with variability in turnaround times, reporting standards, and clinical utility impacting patient outcomes. As the role of the Molecular Tumor Board (MTB) becomes increasingly important in the implementation of evidence-based precision cancer medicine programs, molecular pathology labs must overcome challenges in genomic test interpretation to ensure maximum clinical utility of molecular profiling results.

Join us for, “Clinician Conversations: Improving genomic Test interpretation for real-world cancer care,” a free, virtual event where leading medical directors and oncologists will share practical strategies to enhance the clinical impact of genomic testing. Through real-world case studies from institutions like Dana-Farber Cancer Institute and the National Cancer Institute, attendees will learn how to improve test turnaround, standardize interpretation processes, and deliver comprehensive, personalized genomic reports.

The event will consist of four educational sections:

1. Case Presentations: Clinicians from Dana Farber Cancer Institute and the National Cancer Institute will present cases of how their labs have overcome challenges in genomic test interpretation.

2. Live Q&A Session: Attendees will have the opportunity to ask the clinicians questions about their experiences implementing precision oncology programs at their institutions.

3. Solution Showcase: Experts from QIAGEN Digital Insights will showcase our leading Sample to Insight solutions for molecular tumor profiling.

4. Future Forecast: Discussions on how molecular tumor profiling will change in the next five years and how labs can leverage new technologies to improve patient care.